Tobacco smoking and COVID-19: an old enemy in a new guise. Review of current publications
https://doi.org/10.15829/1728-8800-2020-2604
Abstract
The review summarizes the current data on the relationship of tobacco smoking, e-cigarette use and the novel coronavirus infection COVID-19. The socio-demographic characteristics of patients with COVID-19 and associated diseases, which indicate a possible relationship between smoking and the disease, are analyzed. Recent large meta-analyzes demonstrating the increased risk of progression, the development of severe complications and adverse outcomes of COVID-19 in smokers, as well as in patients with chronic obstructive pulmonary disease, for which smoking is a leading risk factor, are shown. It is believed that tobacco smoking and e-cigarette use causes dose-dependent activation of the angiotensin-converting enzyme-2 receptor, by which virus penetrates to host cell. This may explain the higher risk of complicated COVID-19 in smokers and vapers. There is conflicting data because some studies showed some relatively low smoking prevalence among patients with COVID-19 compared with general population. This, in particular, was associated with poor-quality data collection about smoking, but, nevertheless, was the basis for hypotheses about the protective effect of nicotine against COVID-19. This issue needs further large independent studies, but it is clear so far that smoking is associated with the progression and adverse outcomes of COVID-19.
About the Authors
M. G. GambaryanNational Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Moscow
O. M. Drapkina
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Moscow
References
1. World Health Organization. Coronavirus disease (COVID-19) outbreak https://www.who.int.
2. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239- 42. doi:10.1001/jama.2020.2648.
3. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-20. doi:10.1056/NEJMoa2002032.
4. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5.
5. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020. doi:10.1111/all.14238.
6. Choi KW, Chau TN, Tsang O, et al. Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong. Ann Inter Med. 2003;139:715-23. doi:10.7326/0003-4819-139-9-200311040-00005.
7. Cai H. Sex difference and smoking predisposition in patients with COVID-19. Lancet Respir Med. 2020;8(4):e20. doi:10.1016/S2213-2600(20)30117-X.
8. Cattaruzza MS, Zagà V, Gallus S, et al. Tobacco smoking and COVID19 pandemic: old and new issues. A summary of the evidence from the scientific literature Acta Biomed. 2020;91(2):106-12. doi:10.23750/abm.v91i2.9624.
9. The OpenSAFELY Collaborative, Williamson E, Walker AJ, Bhaskaran KJ, et al. OpenSAFELY: factors associated with COVID19-related hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv preprint doi:10.1101/2020.05.06.20092999.
10. Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis. Arch Acad Emerg Med. 2020;8(1):e35. PMCID: PMC7096724.
11. Lawrence H, Hunter A, Murray R, et al. Cigarette smoking and the occurrence of influenza–Systematic review. J Infect. 2019;79(5):401-6. doi:10.1016/j.jinf.2019.08.014.
12. Liu W, Tao ZW, Lei W, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J. 2020;133(9):1032-8. doi:10.1097/CM9.0000000000000775.
13. Vardavas CI, Nikitara K. COVID-19 and smoking: A systematic review of the evidence. Tob Induc Dis. 2020;18:20. doi:10.18332/tid/119324.
14. Lippi G, Henry BM. Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). Eur J Intern Med. 2020;S0953-6205(20)30110-2. doi:10.1016/j.ejim.2020.03.014.
15. Alqahtani J, Oyelade T, Aldhahir A, et al. Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis. PLOS ONE. 2020;15(5):e0233147. doi:10.1371/journal.pone.0233147.
16. Patanavanich R, Glantz S. Smoking Is Associated With COVID-19 Progression: A Meta-analysis. Nicotine & Tobacco Research. 2020;ntaa082, doi:10.1093/ntr/ntaa082.
17. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. 2020. doi:10.1056/NEJMoa2007621.
18. Farsalinos K, Angelopoulou A, Alexandris N, Poulas K. COVID19 and the nicotinic cholinergic system. Eur Respir J. 2020. doi:10.1183/13993003.01589-2020.
19. Simons D, Shahab L, Brown J, Perski O. The association of smoking status with SARS-CoV-2 infection, hospitalisation and mortality from COVID-19: A living rapid evidence review. (version 3) Qeios. 2020; ID: UJR2AW.4 doi:10.32388/UJR2AW.4.
20. Gilmore А. Review of: Low incidence of daily active tobacco smoking in patients with symptomatic COVID-19. Qeios. 2020; ID: 37F3UD Open Access CC BY Cite. doi:10.32388/37F3UD.
21. World Health Organization. Global Health Observatory (GHO) Data. https://www.who.int/gho/tobacco/use/en/
22. Oakes JM, Fuchs RM, Gardner JD, et al. Nicotine and the reninangiotensin system. Am J Physiol Regul Integr Comp Physiol. 2018;315(5):R895-R906.5. doi:10.1152/ajpregu.00099.2018.
23. Wang J, Luo Q, Chen R, et al. Susceptibility analysis of COVID19 in smokers based on ACE2. Prereprints. 2020;2020030078. doi:10.20944/preprints202003.0078.v.
24. Brake SJ, Barnsley K Lu W, et al. Smoking Upregulates Angiotensin-Converting Enzyme-2 Receptor: A Potential Adhesion Site for Novel Coronavirus SARS-CoV-2 (Covid-19). J Clin Med. 2020;9(3):841. doi:10.3390/jcm9030841.
25. Smith JC, Sheltzer JM. Cigarette smoke triggers the expansion of a subpopulation of respiratory epithe- lial cells that express the SARS-CoV-2 receptor ACE2. bioRxiv. 2020. doi:10.1101/2020.03.28.01367.
26. Leung J M, Yang Ch X, Tam A, et al. ACE-2 Expression in the Small Airway Epithelia of Smokers and COPD Patients: Implications for COVID-19. Eur Respir J. 2020; 55(5):200068. doi:10.1183/13993003.00688-2020.
27. Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell. 2020. doi:10.1016/j.cell.2020.04.004.
28. Farsalinos K, Niaura R, Le Houezec J, et al. Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system, Toxicol Rep. 2020;7:658-63. doi:10.1016/j.toxrep.2020.04.012.
29. Changeux JP, Amoura Z, Rey F, Miyara M. A nicotinic hypothesis for COVID-19 with preventive and therapeutic implications. Qeios. 2020; doi:10.32388/FXGQSB.2.
30. Miyashita L, Suri R, Dearing E, et al. E-cigarette vapour enhances pneumococcal adherence to airway epithelial cells. Eur Respir J. 2018;51(2): 1701592. doi:10.1183/13993003.01592-2017.
31. Martin EM, Clapp PW, Rebuli ME, et al. E-cigarette use results in suppression of immune and inflammatory-response genes in nasal epithelial cells similar to cigarette smoke. Am J Physiol Lung Cell Mol Physiol. 2016;311(1):L135-44. doi:10.1152/ajplung.00170.2016.
32. McAlinden KD, Sohal SS, Sharma P. There can be smoke without fire: warranted caution in promoting electronic cigarettes and heat not burn devices as a safer alternative to cigarette smoking. ERJ Open Research. 2019;5:00114-2019. doi:10.1183/23120541.00114-2019.
33. Werner AK, Koumans EH, Chatham-Stephens K, et al. Hospitalizations and Deaths Associated with EVALI. N Engl J Med. 2020;382(17):1589-98. doi:10.1056/NEJMoa1915314.
34. Bao W, Xu G, Lu J, et al. Changes in Electronic Cigarette Use Among Adults in the United States, 2014-2016. JAMA. 2018;319(19):2039-41. doi:10.1001/jama.2018.4658.
35. Information note on COVID-19 and NCDs-WHO, 23 March 2020. (In Russ.) https://www.who.int/who-documents-detail/covid-19-and-ncds.
Review
For citations:
Gambaryan M.G., Drapkina O.M. Tobacco smoking and COVID-19: an old enemy in a new guise. Review of current publications. Cardiovascular Therapy and Prevention. 2020;19(3):2604. (In Russ.) https://doi.org/10.15829/1728-8800-2020-2604